CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 257 enrolled
Drug / intervention
Evaluation Group +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03518658
NCT03518658N/ACompleted
CompareCT.gov

BlueSync Field Evaluation

Medtronic Cardiac Rhythm and Heart Failure·observational·Posted May 8, 2018·Updated May 6, 2021

In Brief

An observational study evaluating Evaluation Group and Control Group (Historical) for Bradycardia. Completed, enrolled 257 participants across 20 sites in 4 countries.

Detailed Summary

The purpose of this field evaluation is to collect and evaluate information related to CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBradycardia
CountriesFrance, Italy, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 8, 2018
Enrollment StartApr 2, 2018
Primary CompletionDec 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.2 years ago

Interventions

Evaluation Groupother

Patient receiving exposure to the MyCareLink Heart App during device pairing

Control Group (Historical)other

Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.